Pharmacotherapy in children and adolescents with pervasive developmental disorders

Journal of Child and Adolescent Psychiatric Nursing

Volumn 12, Issue 1, 1999, Pages 41-43

  Scahill, Lawrence ^a   Koenig, Kathleen ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; AUTISM; CHILD; DRUG MONITORING; HUMAN; PSYCHOPHARMACOLOGY; REVIEW;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DRUG MONITORING; HUMANS; PSYCHOPHARMACOLOGY; SEROTONIN UPTAKE INHIBITORS;

EID: 0032610990     PISSN: 10736077     EISSN: 17446171     Source Type: Journal    
DOI: 10.1111/j.1744-6171.1999.tb00040.x     Document Type: Article

References (21)

1. American Psychiatric Association. (1994). Dingnostic and statistical manual of niental disorders. Washington, Dc: Author.
2. Anderson, L.T., Campbell, M., Adams, P., Small, A.M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal cf Autism and De?~elopnientnl Disorders, 19,227-239.
3. Bryson, S.E. (1997). Epidemiology of autism: Overview and issues outstanding. In D. Cohen & F. Volkman (Eds.), Handbook of niitisni and perivsive dmcz,elopental disorders. New York: Wiley.
4. Campbell, M., Anderson, L.T., Small, A.M., Adams, I, Gonzalez, N.M., & Emst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal of the American Academy of Child and ALiolfficent P~~~hiatry, 32,1283 -1291.
5. Campbell, M., Anderson, L.T., Small, A.M., Locascio, J.J., Lynch, N.S., & Chom, M.C. (1990). Naltmone in autistic dddren: A doubleblind and placebrrmntrolled study. Psjch@umnau&gy Bulletin, 26,130-1%.
6. Campbell, M., Armenteros, J.L., Malone, R.P., Adams, P., Eisenberg, Z.W., & Overall, J.E. (1997). Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. lournrrl uf the Atriericnti Acadnny of Child and Adolescmit Psychiatry, 36,835-843.
7. Cook, E.H. Jr., Rowlett, R., Jaselskis, C., & Leventhal, B.L. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 739-745.
8. Fisman, S., & Steele, M. (1996). Use of respiridone in pervasive developmental disorders: A case series. Joiirnal of Child mid Adolescent PSychoph~colog!j, 6,177-190.
9. Gordon, C., State, R., Nelson, J.E., Hamburger, S.D., & Rappoport, J.L. (1993). A double blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archizes of General Psychintry, 50,441-447.
10. Jaselslus, C., Cook, E.H., Fletcher, K.E., & Leventhal, B.L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Jounwl of Clinical Pgc@/wniuzcoloa, 12,322-327.
11. Kumra, S., Herion, D., Jacobsen, L.K., Briguglia, C., & Grothe D. (1997). Case study: Risperidone-induced hepatotoxicity in pediatric patients. Joirrnal of the American Acadeniy of Child iind Adolescent Psychiatry, 36,701 -705.
12. McDougle, C. (1997). Psychopharmacology. In D. Cohen & F, Volkmar (Eds.), Handbook of autism and pen~asioe dmelopniental disorders (pp. 707-729). New York: Wiley.
13. McDougle, C., Holmes, J.P., Bronson, M.R., Anderson, G.M., Volkmar, F.R., Price, L.H., & Cohen, D.J. (1997). Repiridone treatment of children and adolescents with pervasive developmental disorders: A prospective, open label study. Journal of the Acadeiny of Child and Adolescent Psychintnj, 36,685 - 693.
14. McDougle, C., Naylor, S.T., Cohen, D.J., Volkmar, F.R., Heninger, G.R., & Price, L.H. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archizles of G~'nera/ Psychintry, 53,1001-1008.
15. Peny, R., Campbell, M., Adams, P., Lynch, N.S., Spencer, E.K., Curren, E.L., & Overall, J.E. (1989). Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. Joirnial of the Acndwfy of Child and Adolescent Psychintq/, 28, 87-92.
16. Qtuntana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., Greenhill, L. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Joiinlnl of Autism and Dn~e/o)~tneiital Disorders, 25,283-294.
17. Ritvo, E.R., Freeman, B.J., Yuwiler, A, Geller, E., Yokota, A, Schroth, P., & Novak, P. (1984). Study of fenfluramine in outpatients with the syndrome of autism. Joiirtwl of Pediatrics, 205,823-828.
18. Scahill, L. (1996). Contemporary approaches to pharniacotherapy in Tourette's syndrome and obsessive-compulsive disorder. Joirrnnl of Child and Adolescent Psychiatric Nursing, 9,27-43.
19. Scahill, L., & Lynch, K.A. (1994). Tricyclic antidepressants: Cardiac effects and clinical implications. Jonriial of Child and Ailolescent Psychiatric Nursing, 7,37-39.
20. Scahill, L., & Lynch, K.A. (1998). Atypical neuroleptics in chddren and adolescents. loirrnal of Child mid Adolescent Psychiatric Nirrsing, 11, 8-42.
21. Strayhom, J., Rapp, N., Donina, W., & Strain, P.S. (1988). Randomized trial of methylphenidate for an autistic child. Joirrnol of the American Academy of Child and Adolescent Psychintry, 27,244-247.